NS6180 did not affect NA-NK cell degranulation in the presence of K562 cells compared with the corresponding condition without potassium channel blockers. In activated NK-92 cells, NS6180 application yielded an apparent current reduction attributed to background (leak) current. In rat hippocampal slices with acetylcholine- and physostigmine-induced gamma oscillations, NS6180 had no significant effect on peak gamma power compared with time-matched controls without drug applications. Preincubation with NS6180 significantly reduced basal intracellular calcium levels in primary NK cells. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Unchanged degranulation in NA-NK cells
Cell-based study · NA-NK cells [1]
NA-NK cells were preincubated with NS6180 at 0.1 µM and 1 µM before addition of K562 cells. Degranulation was unaffected compared with cells exposed to K562 cells without potassium channel blockers.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 µM and 1 µM
- Exposure duration
- 30–45 min before addition of K562 cells; 4 hours later
- Method
- pre-incubated with channel blockers
- Co-treatment
- Other interventions in this design: K562 cells 1∶1 ratio. Compound effect isolated by the comparison: in the presence of K562 cells without potassium channel blockers.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: NS6180
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Degranulation Assays (S37, S38); Results > KCa3.1 Blockade Increases the Degranulation of A-NK Cells and their Ability to Kill K562 Cells (S111); Figure 4 legend (S159)
CD107a expression levels: CD107a expression levels; comparator: in the presence of K562 cells without potassium channel blockers — Results > KCa3.1 Blockade Increases the Degranulation of A-NK Cells and their Ability to Kill K562 Cells (S111); Figure 4 legend (S159)
Apparent current reduction in activated NK cells
Cell-based study · activated NK-92 cell [2]
Typical record of K+ (Kv and KCa3.1) currents from an activated NK-92 cell. After the application of 300 nM of specific KCa3.1 blocker NS6180, instead of the expected 95% block at −150 mV, an apparent current reduction was by 83% only due to a significant background (leak) current.
Literature-Reported Treatment Conditions
- Treatment concentration
- 300 nM
- Method
- bath perfusion
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: IL-2 500 UI/mL; IL-15 0.3 ng/mL. Compound effect isolated by the comparison: The black trace is the control, green trace is after the application of 300 nM of specific KCa3.1 blocker NS6180..
- Reported limits
- Not stated in the sentences used: schedule.
Methods and source locations
Compound reported in the paper: NS6180
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.1. Reagents (S3); 2. Materials and Methods > 2.4. Electrophysiology (S33); 2. Materials and Methods > 2.5. Activation of Primary NK and NK-92 Cells (S38); Figure A2 legend (S173, S175, S176)
K+ (Kv and KCa3.1) currents: K+ (Kv and KCa3.1) currents; comparator: The black trace is the control — Figure A2 legend (S173, S175, S176)
Unchanged gamma power in rat hippocampal slices
Cell-based study · CA3 region of rat hippocampal slices; Wistar rats of both sexes; n = 7, N = 3 [3]
Rat hippocampal slices with acetylcholine- and physostigmine-induced gamma oscillations were treated with 1 μM NS6180. Peak gamma power showed no significant effect compared with time-matched controls without drug applications.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 100 min after induction for 60 min
- Co-treatment
- Other interventions in this design: acetylcholine 10 μM; physostigmine 2 μM. Compound effect isolated by the comparison: time-matched control experiments without drug applications.
- Reported limits
- Not stated in the sentences used: route, vehicle. Removed after verification: value.
Methods and source locations
Compound reported in the paper: NS6180
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods and Materials > Animals and Slice Preparation (S3); Methods and Materials > Extracellular Recordings and Analysis (S14); Results > Activation of KCa2 Channels Inhibits and Blockade Increases Gamma Oscillations (S52, S58); Figure 1 legend (S87, S88)
normalized peak power of hippocampal gamma oscillations: normalized peak power of hippocampal gamma oscillations; comparator: time-matched control experiments without drug applications — Results > Activation of KCa2 Channels Inhibits and Blockade Increases Gamma Oscillations (S58); Figure 1 legend (S87)
Reduced basal calcium levels in primary NK cells
Cell-based study · primary NK cells [2]
Primary NK cells were preincubated with NS6180 at 1 and 10 μM for 20 min. Treatment induced a significant reduction in basal intracellular calcium levels.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 and 10 μM
- Exposure duration
- 20 min
- Method
- preincubated with the blocker
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: control.
Methods and source locations
Compound reported in the paper: NS6180
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.1. Reagents (S3); 2. Materials and Methods > 2.7. Intracellular Ca2+ Measurements (S51, S52, S60); 3. Results > 3.2. Effect of KCa3.1 Block on Intracellular Ca2+ Dynamics in NK Cells and NK-92 Cell Line > 3.2.1. KCa 3.1 Controls Basal [Ca2+]i Level in Resting NK Cells (S115, S117)
basal [Ca2+]i levels: basal [Ca2+]i levels — 3. Results > 3.2. Effect of KCa3.1 Block on Intracellular Ca2+ Dynamics in NK Cells and NK-92 Cell Line > 3.2.1. KCa 3.1 Controls Basal [Ca2+]i Level in Resting NK Cells (S115, S117)